These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 38971642)
1. Targeting cancer stem cells in multiple myeloma. Gunes EG; Gunes M; Yu J; Janakiram M Trends Cancer; 2024 Aug; 10(8):733-748. PubMed ID: 38971642 [TBL] [Abstract][Full Text] [Related]
2. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307 [TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma cancer stem cells. Gao M; Kong Y; Yang G; Gao L; Shi J Oncotarget; 2016 Jun; 7(23):35466-77. PubMed ID: 27007154 [TBL] [Abstract][Full Text] [Related]
5. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway. Wang H; Gong Y; Liang L; Xiao L; Yi H; Ye M; Roy M; Xia J; Zhou W; Yang C; Shen X; Zhang B; Li Z; Liu J; Zhou H; Xiao X Br J Haematol; 2020 Jun; 189(6):1151-1164. PubMed ID: 32167591 [TBL] [Abstract][Full Text] [Related]
6. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718 [No Abstract] [Full Text] [Related]
7. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches. Kizaki M; Tabayashi T J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854 [TBL] [Abstract][Full Text] [Related]
8. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764 [TBL] [Abstract][Full Text] [Related]
9. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864 [TBL] [Abstract][Full Text] [Related]
10. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712 [TBL] [Abstract][Full Text] [Related]
11. The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma. Gunn EJ; Williams JT; Huynh DT; Iannotti MJ; Han C; Barrios FJ; Kendall S; Glackin CA; Colby DA; Kirshner J Leuk Lymphoma; 2011 Jun; 52(6):1085-97. PubMed ID: 21417826 [TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells in multiple myeloma. Ghosh N; Matsui W Cancer Lett; 2009 May; 277(1):1-7. PubMed ID: 18809245 [TBL] [Abstract][Full Text] [Related]
13. An update of novel therapeutic approaches for multiple myeloma. Richardson P; Hideshima T; Anderson KC Curr Treat Options Oncol; 2004 Jun; 5(3):227-38. PubMed ID: 15115651 [TBL] [Abstract][Full Text] [Related]
14. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Hajek R; Okubote SA; Svachova H Br J Haematol; 2013 Dec; 163(5):551-64. PubMed ID: 24111932 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma. Podar K; Jager D Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977 [TBL] [Abstract][Full Text] [Related]
16. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis? Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571 [TBL] [Abstract][Full Text] [Related]
17. Targeting Multiple Myeloma Cancer Stem Cells with Natural Products - Lessons from Other Hematological Malignancies. Issa ME; Cretton S; Cuendet M Planta Med; 2017 Jun; 83(9):752-760. PubMed ID: 28472843 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. Blatt K; Herrmann H; Stefanzl G; Sperr WR; Valent P Oncotarget; 2016 Oct; 7(40):65627-65642. PubMed ID: 27582537 [TBL] [Abstract][Full Text] [Related]
19. Emerging strategies for targeting cell adhesion in multiple myeloma. Nair RR; Gebhard AW; Emmons MF; Hazlehurst LA Adv Pharmacol; 2012; 65():143-89. PubMed ID: 22959026 [TBL] [Abstract][Full Text] [Related]
20. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. Shay G; Hazlehurst L; Lynch CC J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]